Stay updated on Nivolumab in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Resectable NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The page’s revision/version indicator for the ClinicalTrials.gov site has been bumped from v3.5.2 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-24T05:50:03.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:31:34.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Frontend revision updated: v3.5.0 deployed and v3.4.3 removed.
    Difference
    0.0%
    Check dated 2026-03-19T04:51:42.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Revision: v3.4.3 has been added to the page footer, and the previous label Revision: v3.4.2 has been removed.
    Difference
    0.0%
    Check dated 2026-03-11T23:27:21.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and Revision: v3.4.1 along with a government funding status notice were removed. These are housekeeping updates that do not affect the study details or trial information.
    Difference
    0.3%
    Check dated 2026-02-11T11:27:37.000Z thumbnail image
  8. Check
    97 days ago
    Change Detected
    Summary
    Introduced a government funding lapse notice on the page and updated the revision tag from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T06:55:26.000Z thumbnail image

Stay in the know with updates to Nivolumab in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable NSCLC Clinical Trial page.